Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPersimmon Regulatory News (PSN)

Share Price Information for Persimmon (PSN)

Share Price is delayed by 15 minutes
Get Live Data
1,078.50    26.00 (2.47%)
Bid:
1,071.00
Ask:
1,072.00
Spread: 1.00 (0.093%)
Market Cap: £3.46b
PSN Live PriceLast checked at - London Stock Exchange

Intraday Persimmon Share Chart

Trading Statement

8 Jan 2009 07:00

RNS Number : 2994L
Persimmon PLC
08 January 2009
 



TRADING UPDATE - 8 JANUARY 2009

Persimmon plc announces the following trading update ahead of its Preliminary Results for the year ended 31 December 2008, which will be announced on Tuesday 3 March 2009.

Results for the full year will be in line with market expectations. We have legally completed 10,202 units at an average selling price of c. £172,000. This represents a turnover of c. £1.76 billion.

Our emphasis on cash control has resulted in a reduction of total borrowings at the year end to c. £600 million (June 2008: £906 million). As anticipated at the time of our Interim Results on 21 August 2008 we have generated good net cash inflow from operations through the second half of 2008. Close control of work in progress including the focus on sales of stock properties and over 50% reduction in part exchange holdings has resulted in this strong cash generation, despite the previously reported deterioration in trading conditions encountered from early September 2008. The year end borrowings are lower than originally anticipated due to the early receipt of tax repayment following the provisions announced in our Interim Management Statement on 27 October 2008.

Until there is an improvement in the restricted credit conditions currently experienced we will continue to focus on conserving cash. As a consequence the Board does not intend to pay a final dividend this year.

In addition, we have commenced discussions for the planned refinancing of the Group's credit facilities. Having made good progress, our bank syndicate and private placement investors are actively engaged in establishing facilities appropriate for the future needs of the business together with covenants reflective of current credit market conditions.

Whilst we believe that the long term future for the UK housing market remains good, the short term outlook is challenging. However, we currently have forward sales of c. £400 million.

Further details of the Group's performance for the year together with a general market update will be provided with the announcement of our Results for the year ended 31 December 2008, on Tuesday 3 March 2009.

For further information, please contact:

Persimmon plc

Mike Farley, Group Chief Executive

Mike Killoran, Group Finance Director

On 8 January 2009 +44 (0) 207 153 1533

Thereafter: +44 (0) 1904 642 199 

M: Communications

Edward Orlebar:  +44 (0) 207 153 1523 / +44 (0) 7738 724 630

Charlotte McMullen:  +44 (0) 207 153 1549 / +44 (0) 7921 881 800

Marylene Guernier  +44 (0) 207 153 1269 / +44 (0) 7776 303 788

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTBRMRTMMIMBFL
Date   Source Headline
1st May 20257:00 amRNSAGM Trading Statement
25th Apr 202510:54 amRNSHolding(s) in Company
25th Apr 20259:24 amRNSHolding(s) in Company
11th Apr 20254:22 pmRNSHolding(s) in Company
3rd Apr 202510:15 amRNSHolding(s) in Company
2nd Apr 202512:22 pmRNSHolding(s) in Company
1st Apr 202512:03 pmRNSTotal Voting Rights
31st Mar 20253:14 pmRNSDirector/PDMR Shareholding
27th Mar 202510:08 amRNSHolding(s) in Company
25th Mar 20253:14 pmRNSDirector/PDMR Shareholding
24th Mar 20253:35 pmRNSAnnual Report 2024 and Notice of AGM 2025
24th Mar 20252:24 pmRNSHolding(s) in Company
11th Mar 20257:00 amRNSFull Year Results
6th Mar 20252:06 pmRNSHolding(s) in Company
3rd Mar 20253:35 pmRNSHolding(s) in Company
3rd Feb 202512:26 pmRNSTotal Voting Rights
14th Jan 20257:00 amRNS2024 Trading Statement
2nd Jan 20251:00 pmRNSTotal Voting Rights
10th Dec 20243:47 pmRNSDirectorate Change
2nd Dec 20242:11 pmRNSBlock listing Interim Review
2nd Dec 202412:00 pmRNSTotal Voting Rights
6th Nov 20247:00 amRNSQ3 Trading Statement
5th Nov 20241:31 pmRNSHolding(s) in Company
1st Nov 20243:59 pmRNSTotal Voting Rights
1st Oct 20241:19 pmRNSTotal Voting Rights
24th Sep 202412:25 pmRNSDirector/PDMR Shareholding
2nd Sep 20241:44 pmRNSTotal Voting Rights
8th Aug 20247:00 amRNSHalf Year Results
1st Aug 20242:32 pmRNSTotal Voting Rights
23rd Jul 202410:28 amRNSDirectorate Change
1st Jul 20241:10 pmRNSTotal Voting Rights
19th Jun 20242:48 pmRNSDirector/PDMR Shareholding
3rd Jun 202412:33 pmRNSBlock listing Interim Review
3rd Jun 202411:08 amRNSTotal Voting Rights
23rd May 20247:00 amRNSConfirmation of CFO start date
1st May 20241:11 pmRNSTotal Voting Rights
30th Apr 20242:03 pmRNSDirectorate Change
25th Apr 20242:09 pmRNSResult of AGM
25th Apr 20247:00 amRNSQ1 Trading Statement
2nd Apr 20241:49 pmRNSTotal Voting Rights
28th Mar 202412:53 pmRNSDirector/PDMR Shareholding
25th Mar 20244:47 pmRNSDirector/PDMR Shareholding
25th Mar 20242:07 pmRNSAnnual Report 2023 and Notice of AGM 2024
12th Mar 20241:38 pmRNSDirector/PDMR Shareholding
12th Mar 20247:00 amRNSFull Year Results
11th Jan 20246:00 pmRNSDechra Pharmaceuticals
10th Jan 20247:00 amRNSTrading Statement
1st Dec 20234:48 pmRNSBlock listing Interim Review
1st Dec 20234:45 pmRNSTotal Voting Rights
17th Nov 202310:25 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.